Clinical Data — Investor Presentation (October 2006)
30 slides from Clinical Data's investor presentation, Oct 31, 2006
Slide 1: Clinical Data, Inc. Investor Presentation
Clinical Data, Inc. (r) Investor Presentation October 31, 2006
Slide 2: Corporate Snapshot
Corporate Snapshot NASDAQ: CLDA Market Cap: ~$140 million Annualized Revenues of $80.0 million (on a pro forma basis) Approximately 400 employees International presence US, UK, France, Netherlands, Italy & Australia GLP, CLIA, ISO 9001, EN13485, CE
Slide 3: Divisional Structure
Divisional Structure Vilazodone Phase III SSRI/5HT1A
Slide 4: Divisional Overview
Divisional Overview Reorganized CLDA assets and recent acquisitions into three divisions: 1) PGxHealth Division Leading position in pharmacogenetic diagnostics Proprietary, high-margin Therapeutic Diagnostics(tm) High growth area with significant ROI Targeted to payers and providers Vilazodone (SSRI
Slide 5: Corporate Strategy
Corporate Strategy PGxHealth Advance intellectual property and genetic marker development to commercialize scientifically valid and clinically meaningful pharmacogenetic tests Optimize vilazodone franchise: Complete first pivotal trial and identify genetic markers for vilazodone response Cogenics Gr
Slide 6: Key Achievements FY 2007
Key Achievements FY 2007 Built management team Improved financials Q-over-Q Vilazodone Phase III trial enrollment initiated and now > 50% Demonstrated substantial growth in revenue from existing pharmacogenetic tests Familion revenue on track to grow >100% YOY Announced launch of following tests: Wa
Slide 7: Financial Performance
Financial Performance Fiscal 1Q (June 30) Cash used in Operations: $4.3 m v. $8.7 m Fiscal 4Q06 (~ 51% sequential improvement) Revenue (record): $24.8 m v. $23.2 m Fiscal 4Q06 (~ 7% sequential improvement) Up from $12.8 m same quarter last year Cash balance 6/30/06: $19.0 m v. $7.2 m Fiscal 4Q06 Vil
Slide 8: PGxHealth, A Division of Clinical Data
PGx?HEALTH" 4 ADIVISION OF CLINICAL DATA Introducing Therapeutic Diagnostic» CLINICAL & DATA
Slide 9: PGxHealth Focus
PGxHealth(tm) Focus Leverage recent advances in pharmacogenetics with PGxHealth's expertise in genetic marker development and commercialization to provide novel, high value and proprietary diagnostics leading to more efficacious, safer and less-costly, "targeted" therapies. PGxHealth is dedicated to
Slide 10: PGxHealth Overview
PGxHealth Overview PGxHealth is focused on the rapidly emerging growth market of molecular diagnostics High margin business with high growth potential FDA is a strong proponent of the use of pharmacogenetics PGxHealth leverages a wealth of assets and experience in developing genetic markers for clin
Slide 11: PGxHealth Strategy
PGxHealth Strategy Secure IP for genetic markers and associations for Therapeutic Diagnostics development and commercialization Validate and commercialize a growing pipeline of pharmacogenetic tests with limited investment Create high margin, proprietary tests versus traditional, low margin diagnost
Slide 12: Why PGxHealth? Key Differentiators
Why PGxHealth? Key Differentiators Deep understanding of clinical genetics with proven ability to identify clinically valuable, scientifically valid markers Strong in-licensing, validation and commercialization capabilities in pharmacogenetics Experience developing and running complex pharmacogeneti
Slide 13: Value of Clinical Pharmacogenetics
Value of Clinical Pharmacogenetics Substantially reduces therapeutic costs and overall cost-of-care Improves patient outcomes Higher returns compared with traditional diagnostics -- leverages proprietary IP Aligns with quality measures and pay-for-performance initiatives Clinically sound Creates new
Slide 14: Address Unmet Market Needs - Reduce Cost of Trial and Error Treatment
PGxHealth Focus Address Unmet Market Needs - Reduce Cost of Trial and Error Treatment Approach Disease progression Diagnosis Drug 2 Drug 3 Drug 4 Drug 1 Time/Cost Reactive Care Predictive Care Diagnosis Drug 1 PGx Test Time/Cost
Slide 15: Address Unmet Market Needs - Improve Patient Response
PGxHealth Focus Address Unmet Market Needs - Improve Patient Response to Therapeutics Genetic markers can identify those who will best respond to certain drugs
Slide 16: Patient Safety Remains A Major Problem
PGxHealth Focus: Address Unmet Needs Patient Safety Remains A Major Problem Five percent (5%) of all hospital admissions (1.5 million cases) 106,000 deaths, USA annually 2.2 m patients suffer serious, but not lethal, side effects Increased hospital stay length Increased per patient cost - $2,500 ADR
Slide 17: PGxHealth Product Portfolio: Current Test Menu
PGxHealth Product Portfolio Current Test Menu Test Therapy/Pathology Therapeutic Area Cardiac Channelopathies (Acute Cardiac Symptoms) Cardiovascular TPMT Test Multiple: Childhood Leukemia, Drug Toxicity Oncology PGxTest: WARFARIN Anticoagulation Cardiovascular PGxTest: CLOZAPINE Antipsychotics Schi
Slide 18: PGxHealth Product Portfolio: Pharmacogenetic Test Pipeline
PGxHealth Product Portfolio Pharmacogenetic Test Pipeline Test Therapy/Pathology Therapeutic Area Drug Metabolizing Enzymes Various (CYP for Specific Drug Metabolism) Various (CNS, GI, Oncology) UGT1A1 Irinotecan (Camtosar(r)) Oncology NHL - non-Hodgkin's Lymphoma Rituxan(r) - Monoclonal Antibody On
Slide 19: Familion on Track for Strong Year
Familion on Track for Strong Year Apr Q2004 Jul Q2004 Oct Q2004 Jan Q2005 Apr Q2005 Jul Q2005 Oct Q2005 Jan Q2006 Apr Q2006 Jul Q2006 Revenue/Quarter 0 54000 175485.5 215154.5 414275.4 486000.5 611100.5 812700 809293.66 854100 # Tests/Quarter 0 10 33 53 103 135 170 227 234 257 First Two Quarters FY
Slide 20: Vilazodone
Vilazodone cuinicat para
Slide 21: Vilazodone
Vilazodone Primary Indication: Treatment of depression Profile: New generation, genetically guided dual serotonergic antidepressant Mechanism of Action: Unique molecule Both Selective Serotonin Reuptake Inhibitor (SSRI) and 5HT1A partial agonist Development Stage: Phase III clinical trial in progres
Slide 22: Vilazodone Development Plan: Milestones
Vilazodone Development Plan: Milestones Discover genetic markers for response: results Q3 2007 Enrich second pivotal study with these markers Study to be completed 2008 Conduct long-term safety study in parallel with second pivotal study Manufacture commercial supply NDA Filing: mid-2009 Develop Rx
Slide 23: Cogenics, A Division of Clinical Data
CO:GENICS"” © ADIVISION OF CLINICAL DATA Comprehensive Pharmacogenomics and Molecular Services» 24
Slide 24: Cogenics Overview
Cogenics Overview Leading provider of high quality sequencing, gene expression, genotyping, and other molecular services worldwide unique range of services Pharmaceutical, biotech, agricultural, government, and academic firm clients Full range of regulatory compliance Operational sites in the US (Te
Slide 25: Cogenics Service Offerings
Cogenics Service Offerings Molecular Biology Services Genomic Stability Testing Biodistribution Residual DNA Expression Analysis QPCR Extraction and Banking Collection Kits DNA Extraction Laser Capture Microdissection BioBanking Sequencing ABI 3730 Genotyping RFLP Mapping Sequenom Affymatrix microar
Slide 26: Cogenics Key Objectives
Cogenics Key Objectives Moving aggressively toward profitability Establish brand position as major independent provider of pharmacogenomics and molecular services with broad integrated offerings Leverage leading client base Grow regulated services Enhance technology platform base to increase product
Slide 27: Vital Diagnostics Overview
Vital Diagnostics Overview Market Leader in Moderate Complexity Diagnostics Annualized Revenues of ~ $57M ISO 9001, EN13485, CE, FDA Products and Services Analyzers Reagents Consulting/Service Vital Scientific NV Spankeren, The Netherlands - Instrumentation Development and Production Clinical Data S
Slide 28: FY 2007 Objectives
Corporate Overview July 14, 2006 Clinical Data, Inc. (r) FY 2007 Objectives
Slide 29: FY 2007 Objectives
FY 2007 Objectives PGxHealth - Therapeutic Diagnostics: Access new IP for new marker validation and tests; build pipeline Grow Long QT franchise Prepare for new test launches Expand international test distribution Enhance business development activity and form payer and provider relationships Vilazo
Slide 30: Corporate Overview - Investor Inquiries
Corporate Overview July 14, 2006 Clinical Data, Inc. (r) www.clda.com Investor inquiries: John Quirk 1-646-536-7029 Clinical Data, Inc. (r)